Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (18)

2024

  1. FIB-4 score as a predictor of COVID-19-related severity in hospitalized patients

    Revista Espanola de Enfermedades Digestivas, Vol. 116, Núm. 9, pp. 465-471

  2. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

    United European Gastroenterology Journal

  3. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  4. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

    Hepatology, Vol. 79, Núm. 1, pp. 135-148

2023

  1. AEEH «Consensus about detection and referral of hidden prevalent liver diseases»

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 3, pp. 236-247

  2. Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol

    Contemporary Clinical Trials, Vol. 134

  3. Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

    Liver International, Vol. 43, Núm. 9, pp. 1909-1919

2022

  1. Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective

    Seminars in Liver Disease, Vol. 42, Núm. 4, pp. 434-445

  2. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

    Scientific Reports, Vol. 12, Núm. 1

  3. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

    Hepatology, Vol. 76, Núm. 4, pp. 1121-1134

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection

    Journal of Personalized Medicine, Vol. 11, Núm. 7

2020

  1. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  2. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

2018

  1. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349

  2. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))

    Gastroenterologia y Hepatologia

2012

  1. Accuracy of urea breath test performed immediately after emergency endoscopy in peptic ulcer bleeding

    Digestive Diseases and Sciences, Vol. 57, Núm. 7, pp. 1880-1886